Credo Technology vs Synaptics
CRDO and SYNA side by side, both in electronic components and accessories. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRDO and SYNA compare
Credo Technology is the larger company, worth 5.1 times as much as Synaptics ($23.3B against $4.6B).
Credo Technology grew revenue faster over the last twelve months (165% versus 11.4% for Synaptics).
Credo Technology keeps more of each dollar of sales as profit, with a net margin of 33.8% compared with −41.0% at Synaptics.
Credo Technology scores higher on the StockData Score (13 against 3 for Synaptics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRDO | SYNA |
|---|---|---|
| Size and price | ||
| Market cap | $23.3B | $4.6B |
| Share price | $123.95 | $117.36 |
| Change, 1 year | −14.8% | 82.3% |
| Change, 5 years | – | −56.8% |
| Beta (5Y) | 5.43 | 2.04 |
| Employees | – | 1,700 |
| StockData Score | ||
| Total score | 13 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 4 (better) | 0 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 44.1× | – |
| P/S | 14.6× | 3.8× (better) |
| P/B | 8.5× | 4.9× (better) |
| EV/EBITDA | 41.5× | – |
| P/FCF | 53.1× | 45.3× (better) |
| FCF yield | 1.9% | 2.2% (better) |
| Fair value | $78.67 | $93.44 |
| Margin of safety | −57.6% | −25.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 165% (better) | 11.4% |
| Revenue growth, 5Y average | 86.8% (better) | −2.2% |
| Net income growth (TTM) | 330% | – |
| EPS growth (TTM) | 319% | – |
| Profitability | ||
| Gross margin | 67.1% (better) | 44.7% |
| Operating margin | 31.7% (better) | −5.6% |
| Net margin | 33.8% (better) | −41.0% |
| FCF margin | 27.6% (better) | 8.5% |
| Return on equity | 30.7% (better) | −42.2% |
| Return on invested capital | 44.5% (better) | −3.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.90 (better) |
| Current ratio | 7.40 (better) | 1.12 |
| Altman Z-score | 51.00 (better) | 3.33 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | 2.0% |
| Shareholder yield | 0.00% | 2.0% (better) |
| Ownership | ||
| Held by institutions | 70.4% | 107% |
| Held by insiders | 10.8% | 3.1% |
| Insider net buying, 12 months | −$406M | −$8.7M (better) |
| Short interest, % of float | 5.9% | 6.4% |
Go deeper
- CRDO stock overview
- CRDO income statement
- CRDO valuation and score
- SYNA stock overview
- SYNA income statement
- SYNA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.